BR112020022159A2 - urolitina a como intensificador imune - Google Patents

urolitina a como intensificador imune Download PDF

Info

Publication number
BR112020022159A2
BR112020022159A2 BR112020022159-7A BR112020022159A BR112020022159A2 BR 112020022159 A2 BR112020022159 A2 BR 112020022159A2 BR 112020022159 A BR112020022159 A BR 112020022159A BR 112020022159 A2 BR112020022159 A2 BR 112020022159A2
Authority
BR
Brazil
Prior art keywords
compound
formula
cells
stem cells
fact
Prior art date
Application number
BR112020022159-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Christopher Rinsch
Anurag Singh
Davide D'Amico
Pénélope Andreux
William Blanco-Bose
Original Assignee
Amazentis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1807051.6A external-priority patent/GB201807051D0/en
Priority claimed from GBGB1807819.6A external-priority patent/GB201807819D0/en
Application filed by Amazentis Sa filed Critical Amazentis Sa
Publication of BR112020022159A2 publication Critical patent/BR112020022159A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112020022159-7A 2018-04-30 2019-04-30 urolitina a como intensificador imune BR112020022159A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1807051.6A GB201807051D0 (en) 2018-04-30 2018-04-30 Biological enhancer
GB1807051.6 2018-04-30
GB1807819.6 2018-05-14
GBGB1807819.6A GB201807819D0 (en) 2018-05-14 2018-05-14 Biological enhancer
PCT/EP2019/061093 WO2019211294A1 (en) 2018-04-30 2019-04-30 Urolithin a as immune enhancer

Publications (1)

Publication Number Publication Date
BR112020022159A2 true BR112020022159A2 (pt) 2021-01-26

Family

ID=66379918

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020022159-7A BR112020022159A2 (pt) 2018-04-30 2019-04-30 urolitina a como intensificador imune

Country Status (7)

Country Link
US (3) US10792276B2 (https=)
EP (1) EP3787615A1 (https=)
JP (2) JP7557374B2 (https=)
CN (1) CN112512517A (https=)
BR (1) BR112020022159A2 (https=)
MX (2) MX2020011619A (https=)
WO (1) WO2019211294A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4233858T3 (da) 2012-06-27 2025-05-12 Amazentis Sa Forbedring af autofagi eller forøgelse af levetiden ved indgivelse af urolithiner eller forstadier til disse
WO2019211294A1 (en) 2018-04-30 2019-11-07 Amazentis Sa Urolithin a as immune enhancer
WO2020148445A1 (en) * 2019-01-18 2020-07-23 Société des Produits Nestlé S.A. Agents and methods for increasing stem cell function
GB201912107D0 (en) * 2019-08-22 2019-10-09 Amazentis Sa Combination
US20240000747A1 (en) * 2020-11-26 2024-01-04 Daicel Corporation Sirtuin 6 activator
CA3206062A1 (en) 2021-01-27 2022-08-04 Said Oumouch Urolithin derivatives and methods of use thereof
JP2024516187A (ja) * 2021-05-05 2024-04-12 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 幹細胞機能を向上させるためのウロリチン
CN113813255B (zh) * 2021-10-20 2023-09-01 山东大学 尿石素a及其衍生物在肿瘤免疫治疗的应用
GB202219317D0 (en) * 2022-12-20 2023-02-01 Amazentis Sa Methods for improving mitophagy in subjects
GB202308224D0 (en) 2023-06-01 2023-07-19 Amazentis Sa Formulation
CN117180267B (zh) * 2023-10-25 2026-03-13 深圳市第三人民医院(深圳市肝病研究所) 一种尿石素a在制备药物中的应用及药物
WO2025224366A1 (en) * 2024-04-26 2025-10-30 Amazentis Sa Immune health improvers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007127263A2 (en) 2006-04-26 2007-11-08 The Regents Of The University Of California Therapeutic uses of urolithins
DK4233858T3 (da) * 2012-06-27 2025-05-12 Amazentis Sa Forbedring af autofagi eller forøgelse af levetiden ved indgivelse af urolithiner eller forstadier til disse
EP3663287B1 (en) 2013-12-23 2023-09-20 Amazentis SA Process scale synthesis of urolithins
WO2016099947A1 (en) * 2014-12-19 2016-06-23 Halo Life Science, Llc Use of ellagic acid dihydrate in food products and nutraceuticals
US20170304263A1 (en) * 2016-04-20 2017-10-26 John Michael Pezzuto Antioxidative stress compositions, methods of preparing and uses thereof
WO2019163437A1 (ja) * 2018-02-21 2019-08-29 株式会社ダイセル ウロリチン類を含有する破骨細胞分化抑制剤
WO2019211294A1 (en) 2018-04-30 2019-11-07 Amazentis Sa Urolithin a as immune enhancer

Also Published As

Publication number Publication date
MX2020011619A (es) 2021-01-15
MX2023013675A (es) 2024-01-08
EP3787615A1 (en) 2021-03-10
US20230097072A1 (en) 2023-03-30
US20210085642A1 (en) 2021-03-25
US11426380B2 (en) 2022-08-30
JP2024170634A (ja) 2024-12-10
JP7557374B2 (ja) 2024-09-27
US20190328703A1 (en) 2019-10-31
JP2021522296A (ja) 2021-08-30
CN112512517A (zh) 2021-03-16
US12109190B2 (en) 2024-10-08
US10792276B2 (en) 2020-10-06
WO2019211294A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
US12109190B2 (en) Urolithins as immune response enhancers
ES2672871T3 (es) Producto de fermentación del eje embrionario de soja que contiene equol y método de obtención del mismo
ES2523853T3 (es) Uso de un extracto de Wolfberry para mantener y/o restaurar la tonicidad y/o la firmeza de la piel
TW202421775A (zh) 使用鹿茸幹細胞－條件培養基治療細胞生長之組合物及方法
US20200246380A1 (en) Pharmaceutical Composition for Preventing or Treating Autoimmune Disease, and Method for Producing Same
JP6944957B2 (ja) プロテインｌ−イソアスパラギン酸メチルトランスフェラーゼ活性化用組成物
WO2022043407A1 (fr) Compositions destinées au traitement des troubles neurologiques
Jacobs Immunomodulatory effects of bacterial lipopolysaccharide
KR102507470B1 (ko) 스트렙토코커스 피오게네스의 사균체 또는 SpeA 단백질을 포함하는 알레르기 질환의 예방 또는 치료용 약학적 조성물
CN121568678A (zh) 局部抗氧化剂组合物及其使用方法
JP2022517983A (ja) クローナル幹細胞を含むアトピー皮膚炎の予防または治療用薬学的組成物
JP2002080383A (ja) 免疫防御を刺激する組成物における少なくとも１種のアヤメ科植物の少なくとも１種の抽出物の使用
ITTO20070480A1 (it) Impiego di pidotimod, somministrato per via intranasale per potenziare la risposta immunitaria umorale e cellulare antigene-specifica
CA3052131C (en) Pharmaceutical composition for preventing or treating hypersensitivity immune disease, and method for producing same
RU2010125505A (ru) Фармацевтический набор из эмульсии типа "масло в воде" и твердой композиции
CN115243666A (zh) 神经酰胺增殖促进剂
JP4231222B2 (ja) 皮膚基底膜賦活用組成物
US20240209022A1 (en) Novel peptide having anti-inflammatory and tissue regenerative actions
KR101268460B1 (ko) 항알러지용 조성물
KR20240176914A (ko) 비건 김치 유산균의 대사산물을 포함하는 항염증 조성물
EP4463129A1 (en) Skin care composition and uses thereof
KR20160028438A (ko) 전호 추출물을 유효성분으로 하는 Wnt/β-catenin signaling 활성촉진 조성물
Sonthalia et al. Journal of Cosmetology & Trichology
HK40007907A (en) Pharmaceutical composition for preventing or treating autoimmune disease, and method for producing same
WO2018074327A1 (ja) 粘膜免疫調節剤

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]